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The advent of ultrasound recording has expanded the
capabilities for treatment of the fetus in utero. The di-
agnosis of specific disease processes has allowed for pre-
natal intervention by new techniques designed to im-
prove fetal survival. The application of ventricular pacing
in a hydropic fetus with complete atrioventricular (AV)
block is reported. Complete AV block resulted from
maternal collagen vascular disease. The application of
ventricular pacing was to allow for further in utero de-
velopment and for reversal of hydrops fetalis after im-
provement in cardiac output. Despite fetal death 4 hours
Complete atrioventricular (AV) block is usually well tol-
erated in utero during the third trimester unless the ventric-
ular rate is extremely slow or associated cardiac defects
result in AV valve regurgitation. Nonimmunologic hydrops
fetalis may result (1,2), which represents severe fetal cardiac
decompensation due to congestive heart failure. The hy-
dropic fetus with complete AV block will die in utero if
left untreated in almost all cases. At present, a viable hy-
dropic fetus with complete AV block is delivered by ce-
sarean section, and temporary ventricular pacing is initiated
during perinatal resuscitation (3). However, even after this
course, perinatal mortality exceeds 80% (3,4). Because the
prognosis for the hydropic fetus is poor, we have applied a
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after placement of the ventricular pacing lead, this pro-
cedure when applied earlier in the development of hy-
drops may allow for fetal survival.
Ventricular pacing was accomplished without appar-
ent trauma to mother or fetus and no evidence of fetal
injury was seen at necropsy. Therefore, in the fetus who
would otherwise die in utero before the point of viability
ex utero, fetal ventricular pacing may be a rational al-
ternative to current observation.
(J Am Coli Cardiol 1986;8:/434-6)
new technique of maternal transuterine-fetal transthoracic
ventricular pacing.
Case History
Maternal history. A 24 year old white woman, gravida
II para 1-0-0-1, with Sjogren's syndrome was referred for
fetal cardiac eval uation at 27 t/2 weeks' gestational age. Sjo-
greu's syndrome was diagnosed I year previously when she
developed xerophthalmia and had an antinuclear antibody
titer greater than I: 1,000. She was asymptomatic and re-
quired no medications. Normal fetal heart sounds were noted
by Doppler auscultation until 20 weeks' gestation when fetal
bradycardia at 55 beats/min was noted.
Medical management. At 24 weeks' gestation, an obstet-
rical ultrasound examination in another hospital revealed
moderate polyhydramnios and fetal ascites. Fetal cardiac
anatomy appeared normal. Treatment with terbutaline, 5
mg orally every 6 hours, was initiated to increase the fetal
ventricular rate. At 26 weeks' gestation, a follow-up ma-
ternal ultrasound examination suggested depressed right
ventricular contractility and right ventricular dilation. Bi-
lateral pleural effusions developed. Intravenous digoxin, I
mg, was administered over 24 hours and maintenance treat-
ment with oral digoxin, 0.25 mg daily, was begun. She
received intramuscularly 24 mg of betamethasone acetate
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and betamethasone sodium phosphate. Three days later the
fetal ventricular rate was 44 beats/min. Intravenous atro-
pine, 0.25 mg, and an isoproterenol infusion, 2.75 JLg/min,
resulted in maternal tachycardia without change in the fetal
ventricular rate. Spontaneous fetal movement disappeared
and the patient was transferred to this institution.
Fetal echocardiography. Two-dimensional echocardio-
graphic evaluation (Acuson-128) revealed complete AV block
with an atrial rate of 128/min and a ventricular rate of
32/min. A 3 mm pericardial effusion had developed. The
left ventricular shortening fraction was 47% with an internal
diastolic diameter of 10 mm. The right atrial wall was hy-
pertrophied and the right ventricle was markedly enlarged
(16 mm end-diastolic dimension), using the criteria of DeVore
et al. (5). No structlJral defect was present. Pulsed Doppler
sampling (ATL 6(0) in the right and left atria at the level
of the AV valves revealed mild tricuspid and mitral insuf-
ficiency.
Fetal pacing procedures. Informed consent for trans-
uterine transthoracic fetal ventricular pacing was obtained
after extensive discussions with the physicians involved and
a presentation to the parents of all known risks and potential
benefits as well as an explanation of the uncertainties.
The mother was not sedated for the procedure. Xylo-
caine, I%, was infiltrated subcutaneously in the maternal
abdomen . The fetus remained quiet in a left occiput posterior
position. Under continuous sector scanning, a 17 gauge
Tuohy needle was inserted into the uterine cavity and was
advanced into the fetal thorax and into the right ventricle
(Fig . I). Removal of the obturator yielded pulsatile blood
flow. Although considered , no attempt was made to obtain
cardiac blood for arterial blood gases or digoxin level de-
terminations .
An Electro-Catheter Corporation model II-KPJl bipolar
pigtail pacing catheter previously removed from an adult
Pace-lector ™ insertion device was sheathed within a 19 g
epidural catheter, which had been shortened to allow easy
passage of the pacing wire through its lumen . The pacing
apparatus was threaded into the fetal right ventricle and the
pigtail pacing wire advanced out of the sheath . The sheath
and needle were removed, avoiding tension on the slack
wire . The pacing wire was secured with suture to the ma-
ternal abdomen.
The pacing wire was attached to a Medtronic exernal
pulse generator and ventricular pacing was initiated at a rate
of 120/min . Ultrasound examination revealed ventricular
contractions at 120/min . The pacemaker output was de-
creased until ventricular noncapture was apparent with re-
turn to a ventricular rate of 32. The ventricular capture
threshold was 1.5 rnA. The pacemaker was programmed to
6 rnA ventricular output with a rate of 120 beats/min.
Course. The mother was sedated and placed at bed rest.
External Doppler fetal heart tone monitoring revealed a heart
rate of 120 beats/min. Four hours and 15 minutes after
Figure 1. Two-dimensional fetal echocardiograms depicting the
pacemaker lead passing through the chest wall and coiled in the
right ventricle (RV ). The arrow identifies the pacemaker cable;
E = edema of chest wall; P = placenta.
initiation of fetal pacing , intermittent irregular heart tones
were noted . The pacemaker output was increased to 20 rnA.
Ventricular capture did not improve and within 5 minutes
fetal heart sounds were no longer evident. Ultrasound ex-
amination revealed fetal asystole . The pacing catheter had
not changed position and remained in the right ventricle .
There was no hematoma in the ventricular wall and no
thrombi within the ventricles. No change in the pericardial
effusion was evident. The pacing catheter was removed and
labor induced .
Fetal autopsy. At postmortem examination, the heart
was anatomically normal with right atrial and ventricular
enlargement. The entry site in the right ventricle could not
be identified. A serosanguinous pericardial effusion was
present. Immunofluorescent studies were performed using
labeled antibodies to human immunoglobulins G and A and
C3 complement. Deposition of these three proteins was
present in both ventricles.
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Discussion
The application of transuterine-transtho racic fetal pacing
for complete AV block has not been previously reported as
a method of treatment for severe fetal bradyarrh ythmia.
Complete AV block may be a major cause of intrauterine
fetal death in women with collagen vascular disease in whom
the incidence of unexplained fetal death may exceed 10
percent (6). Litsey et al. (7) reported positive immun oflu-
ore scent studies of fetal atria l tissue which identified SSA
(anti-Ro) antib odie s and interruption of the spec ialized myo-
cardial conduction fibers in the fetus . Identi cal findings were
see n in our pat ient.
Medical management. There has been no adequate pre-
natal treatment for hydrops related to fetal bradycardia . When
hydrops devel ops , the ventricular rate is usually less than
50 beats/m in. Becau se this degree of bradycardia probably
repre sents an idioventricular escape rhythm, it is unlikely
that atropine would be effective . Catecholamines and beta-
adrenergic stimulants may be tried but terbu taline and iso-
proterenol were not effective in this patient. .
Goals of fetal pacing. The goa l of fetal transth oracic
ventricular pacing was to provide temp orary acce leration of
the fetal ventricular rate. In the absence of AV valve re-
gurgitation , this should have impro ved cardiac output ~nd
allowed right atrial pressure to return to normal. Had pacing
been effective in maintain ing fetal life , digoxin wou ld have
been used to improve stroke volume and a diuretic agent
used to enh ance resolution of edema.
Limitations of fetal pacing. Fetal transthoracic pacing
has seve ral limitations. The present pacing lead is only
moderately flexible and could become dislodged or cause
injury with vigo rous fetal movement. Fetal movements are
minimal in severe hydrops, but fetal activity should increase
with resolution of congestive heart failure . A longer lead
with greater flexibility is required if prolonged temp orary
or impl antable fetal pacemakers are to be developed. The
external pacing system requires maternal bed rest and pre-
sents a risk of bacteri al chorioa rnnionitis. Delivery of the
fetus would require cesarean section to prevent dislodgment
of the pacing catheter dur ing deli very . The lead would need
to be transected and pacing temp orarily stopped durin g de-
livery . The placenta and fetus must be located in the uterus
in positions that allow access to the heart . It is not known
whether incre asing ventricular rate rapidly with fetal pacing
result s in any metabolic or acid-base imbalances as a con-
sequ ence of increasing myocardial oxygen consumption and
cardiac output. In our patient, a slower acceleration of fetal
cardiac rate might have prevented an adverse outcome.
Application of fetal pacing. Several factors appear fa-
vora ble for future application of intrauterine pacing . The
initial ventricular pacing threshold was extremel y low in
this hydropic fetus. If applicable to other fetuses , this would
potentially allow the use of implantable fetal pacemakers .
Sedation docs not appear necess ary to maintain inactivity
of the hydropic fetus during placement of the pacing lead .
No maternal or fetal morbidity could be directly attributed
to insert ion of the pacing lead . The bipolar pacing lead did
not induce uter ine contractions.
Th is technique requ ires the ex pertise of a team composed
of a perin atologist, ultrasonographer and pediatric electro-
physiologist. It should not be applied in the nonh ydropic
fetus unless physiologic data sugges ting ea rly conges tive
heart failure develop . Because the hydropi c fetus is at such
high risk for death in utero or if delivered , fetal pac ing may
be viewed as a reasonable extreme therapy. The develop-
ment of a research program utilizing an anim al model would
be optimal before the application of this technique on a
routine basis in the human fetus. Obstetrical contraindica-
tions should not be ignored in an attempt to save a hydropic
fetus. However, despite these limitations, fetal pacing should
be considere d for the treatment of the dying fetus with
complete AV block.
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